Merit Medical Systems, Inc
Merit Medical Systems designs, manufactures, and markets proprietary medical devices used in interventional, diagnostic, and therapeutic procedures. Its portfolio is concentrated in cardiology, radiology, oncology, critical care, and endoscopy, with sales split between the United States and international markets.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueCatheters, syringes, access systems, and related devices used in diagnostic and interventional procedures.
Devices used in endoscopic and interventional GI procedures, including acquired products such as EsophyX.
Products used in interventional oncology, pain management, breast cancer surgery, and related procedures.
Devices supporting ICU, imaging, and other hospital-based care settings.
Ancillary products and OEM offerings sold through direct and partner channels.
Customers
Merit sells primarily to hospitals, ambulatory and outpatient access centers, and physician-led procedural departments that need disposable and procedure-specific devices. Its customers buy for clinical performance, reliability, breadth of line, and supply continuity in high-volume interventional workflows.
Buy interventional, critical care, and imaging devices for inpatient and procedural use where reliability and breadth of line matter.
Purchase access, catheter, and procedure devices for cardiology, radiology, and oncology interventions.
Buy endoscopy-related products, including acquired offerings, for therapeutic and diagnostic procedures.
Use Merit devices for outpatient procedures that require sterile, single-use access and intervention products.
Purchase products for incorporation into broader offerings or for distribution in specific geographies.
Strategy
Merit’s strategy centers on growing through R&D, sales model optimization, cost discipline, and operational focus while targeting high-return opportunities in core divisions. Management also emphasizes lean manufacturing, asset utilization, and acquisitions that expand the portfolio, such as Cook Medical and EndoGastric Solutions.
New and improved devices support pricing power, customer retention, and share gains in competitive procedural markets.
Cook Medical and EndoGastric Solutions should broaden the portfolio and add revenue, but only if integration and commercialization succeed.
Lean manufacturing and cost discipline are needed to protect margins in a price-competitive, regulated device market.
Geography
Q1/2026Merit generated 60.0% of 2025 revenue in the United States and 40.0% internationally, so the business is meaningfully exposed to both domestic procedure volumes and foreign currency movements. International growth was driven mainly by EMEA, with additional contribution from Rest of World and Asia Pacific, making regional reimbursement, trade policy, and local competition important to performance.
Share of the revenue the company reports by geography.
Risks
Merit faces execution risk from acquisitions, supply chain and sterilization disruptions, and the challenge of integrating new products into its commercial and IT systems. As a medical device company, it is also exposed to regulatory clearance, product liability, reimbursement pressure, cybersecurity, and foreign exchange volatility, all of which can affect revenue, margins, and compliance costs.
- Supply chain and sterilization disruptionImpact: HighLikelihood: High
Merit relies on third-party vendors and manufacturing/sterilization processes to deliver products on time.
Exposure - Acquisition integration riskImpact: HighLikelihood: Medium
Recent deals must be integrated commercially, operationally, and in IT systems to realize expected benefits.
Exposure: Cook Medical and EndoGastric Solutions acquisitions
- Regulatory and compliance riskImpact: HighLikelihood: Medium
Medical devices require clearance, approval, and ongoing compliance in multiple jurisdictions.
Exposure: U.S. and foreign medical device regulation; Corporate Integrity Agreement
- Foreign exchange and trade policy riskImpact: MediumLikelihood: High
International sales and sourcing expose the company to currency swings, tariffs, and cross-border policy changes.
Exposure - Cybersecurity and data integrity riskImpact: MediumLikelihood: Medium
System breaches or disruptions could affect operations, customer trust, and regulatory obligations.
Exposure
Accounting
Judgemental itemsAcquisitions create goodwill and intangibles that must be tested for recoverability using judgmental cash flow assumptions.
Impact: Could create non-cash charges if acquired businesses underperform
Recent acquisitions add identifiable intangibles and related amortization expense that affect operating profit.
Impact: Impacts comparability of margins and earnings across periods
International sales are exposed to exchange rate fluctuations that can change reported revenue growth.
Impact: Affects reported international sales and margin trends
Procedure-driven demand and product launches can shift quarterly revenue patterns.
Impact: Affects quarter-to-quarter comparability
Similar listed companies
Publicly listed companies with a comparable business focus.
Stryker Corporation
SYK · Surgical & Medical Instruments & Apparatus
IR-Med, Inc.
Electromedical & Electrotherapeutic Apparatus
Medtronic plc
MDT · Electromedical & Electrotherapeutic Apparatus
Medtronic plc designs, manufactures, and sells medical technologies used to diagnose, treat, and manage chronic and acute conditions across the body.
ENvue Medical, Inc.
FEED · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Boston Scientific Corporation
BSX · Surgical & Medical Instruments & Apparatus
Boston Scientific Corporation develops, manufactures, and markets medical devices used across a wide range of interventional specialties.
Inspire Medical Systems, Inc.
INSP · Surgical & Medical Instruments & Apparatus
Inspire Medical Systems develops and commercializes a minimally invasive neurostimulation therapy for obstructive sleep apnea.
Last updated: 24/09/2026